Logo

FDA Expands Approval of Dupixent? (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

Share this
FDA Expands Approval of Dupixent? (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

FDA Expands Approval of Dupixent? (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma